Vol. 20/No. 1 | Oncology Live®

January 11, 2019

Aaron R. Hansen, BSc, MBBS, discusses progress with costimulatory immune checkpoints in oncology.

January 10, 2019

Recently, CDK 4/6 inhibitors have been changing practice in advanced HR-positive breast cancer, with 3 agents now having FDA-approved indications for use with endocrine therapy in the first-line setting.

January 09, 2019

Immune checkpoint inhibitors, with their favorable safety and antitumor activity profiles, have heralded a new era in urothelial carcinoma treatment.

January 08, 2019

Endocrine therapy, commonly used for lengthy periods in the adjuvant treatment of patients with breast cancer, does not have a detrimental effect on cognitive function in survivors of early-stage disease.

January 07, 2019

Study results demonstrate that men and women differ in their immunological responses to foreign and self-antigens.

January 07, 2019

When it works, immunotherapy can dramatically outperform standard of care—for some cancer types, in ways thought unattainable a decade ago.

January 05, 2019

Improvements and greater familiarity with artificial intelligence will lead to systems of checks and balances that will create trust and fulfill the promise of computer-assisted precision medicine.

January 04, 2019

Novel agents are showing impressive ability to cross the blood–brain barrier and impair tumor development in several malignancies, raising the prospect of achieving a long-elusive goal of anticancer therapy.

January 04, 2019

During a recent OncLive Peer Exchange®, a panel of CRC experts discussed the heterogeneity of metastatic CRC and the need to identify patient subsets within this disease to enable a precision medicine approach.

January 03, 2019

The impact of subsequent lines of treatment on trial outcomes can be substantial, seriously challenging the relevance of OS as an objectively meaningful study endpoint.